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DYNAMIC WEDGING: A NOVEL METHOD FOR TREATING
KNEE OSTEOARTHRITIS
Y. Bar-Ziv, Y. Beer, Y. Ran, S. Benedict, N. Halperin
Asaf Harofe Medical Center, Tel Aviv, Israel
Purpose: During the past decades many treatments and devices
were developed in attempt to unload the diseased articular sur-
face in knee osteoarthritis (OA). A novel biomechanical device
and treatment methodology (The APOS System) was introduced
in order to unload the diseased articular surface during activ-
ity (dynamic wedging), strengthen dynamic stabilizers and train
neuromuscular control by means of controlled biomechanical
perturbations. The purpose of this study is to examine the ef-
fectiveness of APOS System in reducing pain and improving
function in knee OA patients.
Methods: A double blind, randomized, prospective study was
performed with 61 knee OA patients, aged 49-83 (66±8.1) years
and graded 1-4 (3±1) according to Kellgren & Lawrence. Patients
were randomized into research (active) and control (placebo)
groups. All patients underwent 8 weeks of treatment. Patients
were examined at baseline and supervised 4 times during the
study. Patients in the research group used the biomechanical
device that consists of 2 biomechanical elements located under
the strategic weight bearing spots of each of the patient’s feet
and a mounting and positioning mechanism embedded in desig-
nated shoes. The treatment methodology that was applied to the
research group included dynamic wedging of the diseased artic-
ular surface. Patients in the control group used a placebo device
without the biomechanical elements. Patients were assessed at
baseline, after 4 weeks and after 8 weeks at the end of the study
using Knee Society Score, WOMAC, SF-36, ALF and VAS. The
assessment was performed without the examiner knowing the
group affiliation of the patient.
Fig. 1
Results: The two groups were statistically similar (p>0.05) at
baseline with respect to age, Kellgren & Lawrence classification
and all assessed parameters including subscales. Significant dif-
ference between groups over time was observed for Knee Score
(p<0.001), Knee Society Function Score (p<0.001), WOMAC
(p<0.001), SF-36 (p<0.001), ALF (p<0.001) and VAS (p<0.001).
Significant improvement was observed in the research group
throughout all assessed parameters (measured improvement for
Knee Score, Knee Society Function Score, WOMAC, SF-36, ALF
and VAS were a multiplication of 1.8, 1.4, 3, 1.4, 1.35 and 2 in
the applicable scale respectively). A slight deterioration was ob-
served in the control group throughout all assessed parameters
at final assessment.
Conclusions: The findings demonstrate that APOS System is
effective and significantly improves function and reduces pain
among knee OA patients.
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D.J. Reda1, H. Shi1, D.O. Clegg2
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Purpose: The Glucosamine/chondroitin Arthritis Intervention
Trial (GAIT) was a double-blind, placebo-controlled, random-
ized, clinical trial comparing glucosamine (G), chondroitin sulfate
(CS), the combination of G and CS, and celecoxib (CE) to
placebo (PL). A high (60.1%) placebo response rate was ob-
served. GAIT patients were not required to flare before study
entry in contrast to many other OA trials. This analysis com-
pares the pain improvement responses of patients who met flare
criteria at entry with those who did not.
Methods: GAIT patients were required to have clinical and
radiographic OA and a summed WOMAC Pain score of 125-400
mm. Patients had screening (V0) and randomization (V1) visits.
Patients had to undergo OA medication washout before V1. Flare
was defined as increases of (a) 15 mm in WOMAC walking pain
and (b) Likert Physician Global of Disease Severity ≥1 between
V0 and V1. Response was defined as 20% improvement in
summed WOMAC Pain between randomization and 6 months of
treatment, and by OMERACT/OARSI criteria (O/O).
Results: 1583 patients were recruited to the study and random-
ized into the five treatment arms. 22.9% met the flare criteria.
Demographics were similar among the treatment groups. The
mean age was 58.6 years, 64.1% were female, mean summed
WOMAC pain was 235.9 and 38.2% were Kellgren & Lawrence
Grade 3. Response rates are summarized in the tables below:
All randomized patients (N=1583)
G CS G+CS CE PL
20% Response 64% 65.4% 66.6% 70.1% 60.1%
Effect Size 0.08 0.10 0.13 0.21
O/O Response 60.6% 63.5% 65.6% 67.3% 56.9%
Effect Size 0.08 0.14 0.18 0.21
Patients meeting flare criteria (N=362)
G CS G+CS CE PL
20% Response 62.7% 68.8% 73.9% 74.6% 69.3%
Effect Size -0.14 -0.01 0.10 0.12
O/O Response 61.4% 68.8% 72.5% 70.4% 68.0%
Effect Size -0.14 0.02 0.10 0.05
Patients not meeting flare criteria (N=1221)
G CS G+CS CE PL
No Flare (N=1221)
20% Response 64.5% 64.6% 64.5% 68.8% 57.1%
Effect Size 0.15 0.15 0.15 0.24
O/O Response 60.3% 62.2% 63.7% 66.4% 53.4%
Effect Size 0.14 0.18 0.21 0.27
Conclusions: Differences between active treatments and
placebo are smaller in patients who flare because placebo re-
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sponse is higher in these patients. Treatment effect sizes are
larger among patients who do not flare.
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MANAGEMENT OF SYMPTOMATIC HAND OA (HOA)
PATIENTS IN AMBULATORY PRACTICE IN FRANCE:
A CROSS-SECTIONAL SURVEY
E. Maheu1, P. Coste2, A. Lafuma3, R.-L. Dreiser4
1St Antoine Hospital, Paris, France, 2Expanscience
Laboratories, Courbevoie, France, 3CEMKA - EVAL, Bourg La
Reine, France, 4Bichat Hospital, Paris, France
Purpose: Few clinical trials have been performed in HOA. De-
spite the recent presentation of the European Ligue Against
Rheumatism recommendations, few is known with respect to the
way doctors treat symptomatic HOA patients.
Aim of this study: To describe the therapeutic uses of French
doctors in HOA according to the level of symptoms.
Methods: Prospective cross-sectional pharmacoepidemiologic
survey. A sample of 100 French rheumatologists (Rh) and 100
general practitioners (GPs) had to describe 2 HOA patients
presenting consecutively: either with a flare of symptoms, i.e.
pain score ≥ 50 mm on a VAS and functional index for hand OA
score (FIHOA [2]) ≥ 5, and or with quiescent symptoms (pain <
50 mm and FIHOA < 5). Patients were both genders, age ≥ 45
years, fulfilling the ACR criteria [1], and were initially separated
according to the level of symptoms. Data collected: Doctors
characteristics, patients demographic data and HOA description,
and treatments received. A pharmaco-economic evaluation was
also performed. Statistics: descriptive: numbers (%) and mean
(SD).
Results: 169 doctors (aged 50 years, 69% men) described 316
patients of which 178 (56%) were in the "flare" and 44% in the
non-flare group, 83% women (95% menopaused), mean age 66
years (10), mean BMI 25 (4), with a familial history of HOA in
60%. VAS Pain score rated 66 (9) mm in the flare group and
30 (11) mm in the non-flare group, and FIHOA averaged 12 (4)
and 4 (1) respectively. Treatments received: 88% in the flare
group vs 76% received level 1 or 2 analgesics (p = 0.004), 69%
vs 30% received an NSAID (p < 0.001) of whom 66 and 50%
were prescribed a gastroprotective drug respectively. 90% of the
patients in the flare group were prescribed a symptomatic slow-
acting drug in OA (SySADOA) vs 80% (p = 0.01). No difference
was observed between the groups regarding the duration of
treatments with the exception of level 1 analgesics (46 days
in the "non-flare" group vs 27; p<0.001). Topical NSAIDs were
used in 60% of patients in both groups. Steroids intra-articular
(IA) injections were performed in 16% of patients in the "flare"
group vs 4% (p < 0.001). Surprinsingly non pharmacological
therapies were more often used in "flare" patients: 38% vs 27%
(p = 0.03), and comprised physical therapy (10%), splints (22%)
and Spa therapy (6%). GPs prescribed more analgesics (93% vs
73%), more NSAIDs (62% vs 43%) and more physical therapy
(19% vs 3) than Rh. Conversely, Rh prescribed more splints
(30% vs 13), and more IA steroids (16% vs 5). Mean costs of
treatments were similar in both groups of patients (278 Euros,
patient’s perspective). Drugs accounted for 189 Euros in the
"flare" group vs 206.
Conclusions: We observed some differences between Rh and
GPs in their management of hand OA symptoms: more splints, IA
steroids injections and SySADOA prescription by RH, while GPs
use more analgesics/NSAIDs and surprisingly more physical
therapy. Further studies in this field are required to confirm our
results.
Funding: This study was financially supported by Expanscience
Laboratories (Courbevoie, France)
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THE SAFETY AND EFFICACY OF ROUTINE
PERI-OPERATIVE NSAIDS PROPHYLAXIS FOR ECTOPIC
BONE FORMATION AFTER HIP REPLACEMENT
SURGERY (HIPAID). A RANDOMISED CLINICAL TRIAL
M. Fransen
The HIPAID Collaborative Group, The George Institute,
Camperdown, Australia
Purpose: To determine the benefit and risk of NSAID-based pro-
phylaxis for ectopic bone formation amongst patients undergoing
total hip replacement (or revision) surgery.
Methods: A double-blind randomised placebo-controlled clini-
cal trial, stratified by treatment site and surgery (primary or
revision), was conducted in 20 orthopaedic surgery centres in
Australia and New Zealand. 902 patients undergoing elective
primary or revision total hip replacement surgery were randomly
allocated to 14 days treatment with ibuprofen (1200mg daily)
or matching placebo commenced within 24 hours of surgery.
Patients were only excluded if there was, in the opinion of the
responsible physician, a definite indication or contra-indication
for treatment with an NSAID during the 14 day study treatment
period. Outcomes were assessed 6 to 12 months after sugery
and included changes in self-reported hip pain and physical func-
tion (WOMAC), physical performance measures and radiographic
evidence of ectopic bone formation.
Results: There was only a 6% loss to follow-up for self-report
measures and a 12% loss to follow-up for radiographs. Six to
twelve months after surgery, there were no significant differences
between the ibuprofen and placebo groups for improvements in
hip pain (mean difference, 95% confidence interval: -0.1, -0.4
to 0.2, p = 0.6) or physical function (-0.1, -0.4 to 0.2, p = 0.5),
despite a much reduced risk of ectopic bone formation (relative
risk 0.69, 95% confidence interval 0.56 to 0.83) associated with
ibuprofen. There was a significantly increased risk of major
bleeding complications during the admission period (2.09, 1.00
to 4.39).
Conclusions: These data, from the largest-ever trial of prophy-
laxis against ectopic bone formation, do not support the use of
routine NSAIDs-based prophylaxis for patients undergoing total
hip replacement surgery.
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VOLUME AND PATIENT REPORTED OUTCOMES
FOLLOWING REVISION TOTAL KNEE REPLACEMENT
J.N. Katz1, N.N. Mahomed2, J.W. Wright1, A.H. Fossel1,
E.A. Wright1, J.A. Baron3, J. Barrett3, E. Losina1
1Brigham and Women’s Hospital, Boston, MA, 2University of
Toronto, Toronto, ON, Canada, 3Dartmouth Medical School,
Lebanon, NH
Purpose: Over 30,000 revision total knee replacements are per-
formed annually in the US, and the number is rising steadily.
Hospital and surgeon procedure volume are associated with
perioperative mortality and complications as well as patient re-
ported functional outcomes two years following primary TKR.
The objective of this study is to determine if hospital and sur-
geon volume of TKR as associated with pain, functional status,
range of motion and satisfaction two years following revision
TKR.
Methods: We used Medicare claims to identify all patients in
four states (IL, OH, NC, TN) who had revision TKR in 2000.
We contacted these patients by mail in 2002 and invited them
to participate in a survey to assess their outcomes of revision
TKR surgery. The survey included the pain and function sub-
